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Background: Cystic echinococcosis (CE), caused by Echinococcus granulosus metacestode, invokes a serious public
health concern. Early diagnosis has great impacts on reduction of disability-adjusted life years. Several antigen
B-related molecules (EgAgB; EgAgB1-5) are known to be immunopotent, but detection of EgAgB is variable in
many patients and may not allow reliable interpretation of its immunological relevance. More importantly, the
immunoproteome profile of hydatid fluid (HF) has not been addressed.
Methods: We conducted a proteome analysis of the HF of a single fertile cyst of CE1 and CE2 stages through
two-dimensional electrophoresis (2-DE). Each protein spot was analyzed by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF-MS). We subsequently determined the immunoproteome
profile employing patient sera of entire disease spectrum from CE1 to CE5 stages.
Results: We identified 40 parasite proteins, of which EgAgB (28 spots) and antigen 5 (EgAg5; 5 molecules) were
abundant. EgAgB proteoforms constituted the majority, mostly EgAgB1 (24 spots), followed by EgAgB2 and EgAgB4
(2 spots each). EgAgB3 was detected only by liquid chromatography-MS/MS. EgAgB5 was not recognized. We also
detected 38 host proteins, which were largely composed of serum components, antioxidant/xenobiotic enzymes,
and enzymes involved in carbohydrate metabolism. CE1 and CE2 HF exhibited comparable spotting patterns, but
CE2 HF harbored greater amounts of EgAgB and EgAg5 complexes. CE sera demonstrated complicated immune
recognition patterns according to the disease progression; CE2 and CE3 stages exhibited strong antibody responses
against diverse EgAgB and EgAg5 proteoforms, while CE1, CE4, and CE5 stages mainly reacted to EgAg5 and
cathepsin B. Patient sera of alveolar echinococcosis (AE) cross-reacted with diverse EgAgB isoforms (36%). EgAg5
and cathepsin B also demonstrated cross-reactions with sera from neurocysticercosis and sparganosis.
Conclusions: Our results demonstrated that detection of a single defined molecule may not properly diagnose CE,
since specific immunodominant epitopes changed as the disease progresses. Immunoproteome analysis combined
with imaging studies may be practical in the differential diagnosis of CE from AE and other cystic lesions, as well as
for staging CE, which are pertinent to establish appropriate patient management.
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Cystic echinococcosis (CE), caused by Echinococcus gran-
ulosus metacestode, is one of the most deleterious hel-
minthic diseases of humans and livestock. CE is detected
worldwide, but it is more prevalent in the nomadic areas
of Central and Middle Asia, Eastern Europe, Africa,
Australia, South America, and northwestern China [1-3].
Approximately 4 million people are infected and another
40 million are at risk of infection annually [4]. Humans
are infected by incidental contract with the eggs in asso-
ciation with dog rearing environments. Oncospheres
hatched from the eggs are activated in the small intestine
and subsequently penetrate the intestinal wall to enter the
circulation. They mostly egress in the liver and lung, and
grow slowly to hydatid fluid (HF)-filled cyst, in which
many protoscoleces and daughter cysts develop [5].
Clinical manifestations of CE are rarely present until
large cyst(s) crowd the affected organs/tissues. Approxi-
mately 60-88% of patients with cysts less than 7.5 cm in
diameter manifest no discernible symptoms [6,7]. Most
CE cases are diagnosed ages between the third and fifth
decades, but the highest morbidity has been observed in
young patients under the first two decades [8]. Therefore,
early detection significantly reduces morbidity and mortal-
ity associated with CE, which remains with challenging
issues. The diagnosis of CE largely depends on imaging
scans and serological tests. However, imaging diagnosis
modalities, such as ultrasonography (US), computed
tomography (CT), and magnetic resonance imaging
(MRI), necessitate differential diagnosis from alveolar
echinococcosis (AE), cystic lesions, liver cirrhosis, and
primary hepatocellular carcinoma [5,9]. Staging of CE
is also ambiguous in many cases. In such complex situa-
tions, serodiagnosis provides additional evidence for CE in
patients with hepatic/pulmonary lesions and is beneficial
to screen and diagnose patients in endemic areas [10].
Several component proteins of HF, such as diverse iso-
forms of antigen 5 (EgAg5) and antigen B (EgAgB) are
known to be potent diagnostic antigens, among which
native and recombinant EgAgBs are reliable and reprodu-
cible antigens that allow for better diagnostic performance
[5,11,12]. EgAgB is a thermostable, macromolecular multi-
functional lipoprotein encoded by a multigene family [13].
At least 10 genes in five subclasses are differentially
expressed from the parasite [14]. Its functions include
elastase inhibition, augmentation of TH2-biased immune
responses, and sequestration of hydrophobic substances
[11,15-17]. However, it has not been critically determined
whether specific antibodies against EgAgB are detected in
both the active and chronic stages of the disease or
whether EgAgB shows species-specificity. Demonstration
of specific antibodies against EgAgB varies from patient
to patient, which does not allow clinical interpretation
of its immunological significance [5,11,16,18,19]. Moreimportantly, aspects of the immunoproteome profile, such
as global antibody responses and alteration of specific
antigens in relation to disease characteristics have not
been investigated.
In the present study, we analyzed the proteome profile
of a single fertile cyst of CE1 and CE2 stages through
matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF-MS), and identified 40
parasite proteins, in which EgAgB (28 spots) and EgAg5
(5 molecules) were abundant. We subsequently determined
their antigenic properties along with CE progression, as
well as their cross-reactions with sera of AE and other dis-
eases. Our results demonstrate that immune recognition
patterns change with disease characteristics, and further
suggest that simultaneous monitoring of the immunopro-
teome profile and imaging scans might be required to
properly diagnose and appropriately manage CE patients.
Methods
Parasite samples
Hepatic CE cysts were obtained from the naturally infected
sheep slaughtered in Xining, Qinghai Province, China. Indi-
vidual cysts were examined by US, and fertile CE1 and CE2
cysts were independently collected. After careful decortica-
tion, the cyst surface was washed with physiological saline
more than 10 times at 4°C. Each HF was aseptically drawn
from intact cysts in the presence of a protease inhibitor
cocktail (one tablet/25 ml, Roche, Germany) and centri-
fuged at 20000 × g for 1 h at 4°C. Supernatants were con-
centrated by lyophilization and stored at −80°C until use.
Study subject and serum samples
Sera of 59 hepatic CE patients (37.1% male), whose disease
statues were defined by US [3], were studied. Patients of
CE1 stage (n = 11) showed unilocular hypodense cyst(s)
with a double line sign. CE2 patients (n = 12) presented
with multivesicular, multiseptated cysts with detached
endocysts. Patients of CE3 (n = 12) demonstrated unilocu-
lar cysts with daughter cysts that contained a solid cyst
matrix or detached endocyst. CE4 patients (n = 13) showed
typical canalicular structure (ball of wool appearance). CE5
patients (n = 11) presented with heavily degenerative cyst
(s) with calcified wall. Involvement of the right lobe was
frequent (71%). Eleven patients (18.6%) had multiple
cysts. Most patients (85%) did not complain of specific
symptoms/signs. Their demo-epidemiological profile, cyst
locations, and representative US findings are summarized
in Additional file 1. In addition, this study included 10 sera
per each of the following groups: neurocysticercosis,
AE, sparganosis, pathology-proven primary hepatocellular
carcinoma, and healthy controls, all of whom denied any
possible exposure to protozoan and helminthic infections
[5,20]. Study protocol was approved by the Institutional
Review Committee of Qinghai Province Institute for
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2013-7-22). The study was presented to the local health
authorities, community leaders, and patients to ensure
their acceptance and collaboration. Written informed con-
sent was obtained from all patients. In the case of illiterate
patients, consent was obtained by verbal notification.
Two-dimensional electrophoresis (2-DE) and immunoblotting
Each HF (200 μg) mixed with rehydration buffer (6 M
urea, 2 M thiourea, 2% CHAPS, 0.4% dithiothreitol [DTT],
0.5% immobilized pH gradient [IPG] buffer and 0.002%
bromophenol blue [BPB]), was cup-loaded on IPG strips
(pH 6–11, 13 cm; GE Healthcare, Piscataway, NJ, USA),
focused for a total of 25 kVh, processed with 15% SDS-
PAGE (160 × 160 × 1.5 mm), and stained with Coomassie
Brilliant Blue G-250 (CBB). For immunoblotting, proteins
separated by 2-DE were electroblotted to nitrocellulose
membranes (Santa Cruz, Dallas, TX, USA) for 8 h at 4°C.
The membranes were blocked with Tris-buffered saline
(100 mM, pH 8.0) containing 3% skim milk and 0.1%
Tween-20 for 1 h. The blots were incubated with individ-
ual and/or pooled serum overnight (1:1000-dilution) at 4°C
and sequentially with horse-radish peroxidase (HRP)-con-
jugated anti-human IgG (Cappel, Solon, OH, USA) for 2 h
(1:4000-dilution). For quantitative analysis, all signals were
detected with SuperSignal Chemiluminescence (ECL; GE
Healthcare) after a 2 min exposure. Images were digitalized
with an Umax Image Scanner (Dallas, TX, USA) and ana-
lyzed employing Progenesis software (Nonlinear Dynamics,
Newcastle, UK). The individual spots, whether stained or
immunoblotted, were quantified by calculation of the spot
volume using the total spot volume normalization method,
multiplied by the total area of all the spots.
Matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF-MS) and nano-liquid
chromatography-electrospray ionization/multi-stage MS
(nano-LC-ESI-MS/MS)
Two different sets of in-gel trypsin-digested protein
spots from each CE1 and CE2 HF were independently
applied using the AB SCIEX TOF/TOF 4800 Plus System
(AB SCIEX, Framingham, MA, USA). Internal standards
were tryptic autodigestion peaks (m/z = 842.5099 and
2211.1046). Monoisotopic peptide masses were selected
between 600 and 3500 Da. The proteins were identified by
peptide mass fingerprint (PMF) with a Mascot server.
Mass tolerance was ± 50 ppm. One missed cleavage site
was allowed. Identification was accepted when PMF har-
bored at least two identified peptides (>99% probability).
For nano-LC-ESI-MS/MS, CE1 and CE2 HF were sep-
arated by 15% reducing SDS-PAGE and visualized with
CBB staining. Each band corresponding to 24 kDa was
cut and sliced into fragments from independent gels.
Disulfide bonds were reduced with 10 mM DTT. Afteralkylation, gels were dehydrated, trypsin-digested, and
dried in a vacuum evaporator (MIVAC DUO, Genevac,
Ipswich, UK). Analysis was conducted employing a model
1200 nano-flow system (Agilent Technologies, Palo Alto,
CA, USA) connected to a LTQ linear ion trap mass spec-
trometer (Thermo Electron, San Jose, CA, USA). The
reversed phase capillary column was 12 cm in length,
75 mm in inner diameter, and in-house packed with 5 μm
200 Å pore-sized Magic C18AQ beads (Michrome BioRe-
sources, Auburn, CA, USA). The peptides were eluted in
a linear gradient from 10 to 40% acetonitrile over 65 min.
MS survey was scanned for 300–2000m/z with three
data-dependent MS/MS scans of isolation width (1.5m/z),
normalized collision energy (25%), and dynamic exclu-
sion duration (180 sec). MS data was generated in
RAW file format (Thermo Scientific) using the Xcalibur
1.4 with Tune 1.0. Peptide peaks were introduced into
MS/MS ions search within a Mascot server (http://
www.matrixscience.com). Mass values were selected using
monoisotopic masses. Peptide and MS/MS tolerances
were ± 1.2 and ± 0.6 Da. Protein identifications of indi-
vidual ions scores > 43 were considered as significant or
to demonstrate extensive homology (p < 0.05).
Cysteine carbamidomethylation and methionine oxida-
tion were considered during the analyses. MS database
search was performed on the NCBI database (http://www.
ncbi.nlm.nih.gov). Signal peptide sequences were predicted
by SignalP 4.1 (http://www.cbs.dtu.dk/services/SignalP/)
and PSORT (http://psort.hgc.jp/form.html).
Results
Proteomic analysis of E. granulosus HF collected from
different CE stages reveals similar spotting patterns, but
CE2 HF harbored enriched EgAgB and EgAg5 proteoforms
In order to comparatively delineate HF proteins of dif-
ferent CE stages, we determined the protein profile of a
single fertile CE1 and CE2 cyst. As shown in Figure 1A
and B, equivalent spotting patterns were evident, but CE2
HF harbored more EgAgB than CE1 HF. The expression
pattern of EgAg5 was also shown to be upregulated in
CE2 HF (see also Table 1). We identified 78 protein spots
(p < 0.01); 40 Echinococcus and 38 host proteins. All the
Echinococcus proteins were concomitantly identified; they
typically segregated into diverse isoforms of EgAgB and
EgAg5. EgAgB proteoforms appeared to be encoded by six
different genes (ACZ51458, ACZ51459, and ACP21247
for EgAgB1; AAP83174 and AAW78457 for EgAgB2; and
ACZ51452 for EgAgB4). Among the EgAgB complex,
EgAgB1 was the major components comprising 24 mole-
cules between 8 and 16 kDa (spots 43–49, 60–74, 77, and
78). Each of two EgAgB4- (spots 58 and 59) and EgAgB2-
related proteins (spots 75 and 76) was recognized. EgAgB3-
and EgAgB5-related molecules could not be identified. This
result matched well with previous studies in which EgAgB1,
Figure 1 Electrophoretic profile of E. granulosus HF collected from sheep livers. HF (200 μg proteins) harvested from single fertile cyst of
CE1 (A) and CE2 (B) stages were electrofocused on IPG strips (pH 6–11) and resolved by 15% SDS-PAGE. The gels were stained with CBB. The
protein spots were subjected to in-gel trypsin digestion and processed with MALDI-TOF-MS. Proteins identified are marked by Arabic numbers
(1–78) and are summarized in Table 1 and Additional file 2. Representative ultrasonographic images of CE1 and CE2 cysts are shown. Mr, molecular
weights in kDa; pI, isoelectric point.
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expressed among several EgAgB isoforms [14,21]. Five
EgAg5 isoforms/variants were detected (spots 21 and
23–26; ADG65665). Other molecules (7 spots) included en-
zymes involved in carbohydrate metabolism (5 molecules),
such as phosphoenolpyruvate carboxykinase (spot 2),
citrate synthase (spot 10), phosphoglycerate kinase (spot
11), fructose 1,6 biphosphate aldolase (spot 22), and trio-
phosphate isomerase (spot 32), and proteolytic cathepsin B
(2 molecules; spots 7 and 9) (Table 1 and Additional file 2).
We also identified 38 host-derived ovine proteins. These
molecules mainly consisted of serum components (sero-
transferrin, carbonic anhydrase, and immunoglobulin and
hemoglobin families). In addition, antioxidant/detoxifi-
cation/xenobiotic proteins (selenium-binding protein 1,Table 1 Identification of E. granulosus proteins in CE1 and CE
Spot no(s). Theoretical Mr/pI Accessio
2 55590/8.39 CBH3649
7, 9 39841/6.82 EgrG_000
10 51345/8.26 EgrG_001
11 44227/8.03 EUB59398
21, 23-26 33316/9.02 ADG6566
22 39666/8.31 EgrG_000
32 27123/6.60 EgrG_000
43-49, 60–71, 74, 77, 78, 6232/8.31 ACZ5145
72 5348/9.30 ACP2124
73 7223/9.23 ACZ5145
58, 59 8337/6.78 ACZ5145
75 9282/9.38 AAW7845
76 9314/9.38 AAP8317
aProtein names were adopted from the GenBank database. MALDI-TOF-MS analysis
bThe presence of a signal peptide (SP) sequence was predicted by SignalP 4.1 anddihydrodiol dehydrogenase 3, peroxiredoxin-1, and gluta-
thione transferases), enzymes involved in carbohydrate
(sorbitol dehydrogenase and alcohol dehydrogenase) and
amino acid metabolism (fumarylacetoacetase), fatty-acid-
binding proteins (lipid transporter), phosphatidylethanol-
amine-binding protein (signaling molecule), oxidoreductase
(glycerol-3-phosphate dehydrogenase and carbonyl reduc-
tase), sugar-binding galectin-3, and γ-tubulin were detected
(Additional file 2).
Immune recognition profile of HF against sera of different
CE stages are altered along with CE progression and
differed from one another
The EgAgB complex has been well known to induce spe-
cific antibody responses against CE sera [1,5,10,11,16],2 cysts by MALDI-TOF-MS
n no Descriptiona SPb
0 Phosphoenolpyruvate carboxykinase -
790200 Cathepsin B +
028500 Citrate synthase -
Phosphoglycerate kinase -
5 38 kDa antigen 5 -
905600 Fructose 1,6 bisphosphate aldolase -
416400 Triosephosphate isomerase -
9 EgAgB1/1 +




4 EgAgB subunit 2 +
was duplicated for each HF sample from CE1 and CE2 stages.
PSORT.
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changes of specific epitopes along with CE characteristics
have not been explored [19]. In order to establish a global
immunoproteome profile, we observed the immunorecog-
nition pattern of HFs of sheep CE1 and CE2 cysts by using
pooled patient serum from CE1-CE5 stages (n = 3 per
group). These HFs demonstrated an immunoreactivity
profile similar to each other, but CE2 HF exhibited more
distinct patterns than CE1 (left panel, Figure 2A; other
data not shown). We used CE2 HF to compile the CE
immunoproteome.
When blots containing CE2 HF were probed with a
pooled CE patient serum, cathepsin B (spots 7 and 9),
EgAg5 (spots 23–26), and diverse EgAgB proteoforms
demonstrated strong antibody reactions in a highly com-
plicated fashion. Interestingly, five to seven spots located
at approximately 24 kDa, which could not be identified
through MALDI-TOF-MS analysis, displayed positive re-
actions (box, Figure 2A). We analyzed the correspondingFigure 2 Global immunoproteome characteristics of CE2 HF. (A) Immu
The patients were classified by typical US findings [4]. CE2 HF was separate
pooled CE1-CE5 sera (n = 3 per group) as described in the Methods section
(red), EgAgB subunit 2 (khaki), EgAgB2 (brown), and EgAgB4 (green) are ind
ca. 24 kDa could not be identified on 2-DE gel, but showed immunoreactiv
was independently analyzed by nano-LC-ESI-MS/MS. (B) Identification of pr
Figure 1A (left panel) was compared to the volumes of the corresponding
and normalized protein volumes (right Y-axis) in the CBB stained gels. Theband (right panel, Figure 2A) by LC-ESI-MS/MS and
recognized that this band contained EgAgB1, EgAgB2,
EgAgB3, and EgAg4 isoforms (Figure 2B).
Among the diverse EgAgB proteoforms, EgAgB1
(spots 44, 61–69, 71, 73, 74, and 77) revealed high anti-
body capturing activity, which comprised 55.1% of the
total volume of the proteins and 80.2% of the total
volume of the antigenic spots (dotted-boxes, Figure 2C).
Other EgAgB subunits, such as EgAgB2, EgAgB3, and
EgAgB4 exhibited minimal antibody reactivity. This
result convincingly demonstrated that EgAgB1 isoforms
constituted immunodominant antigens.
We subsequently determined that the alteration of
immunoreactive spots in accordance with CE involution
(Figure 3). When we probed individual CE1 sera, immu-
noreactions against EgAg5 (spots 23–26) and cathepsin
B (spot 9) were fairly high (36.4-72.7%). Conversely,
EgAgB1 isoforms, such as spots 47, 48, 61, 63, 66, 67,
69, 72–74, and 77 showed relatively weak responsesnoproteome analysis of HF against pooled sera of different CE stages.
d by 2-DE, transferred to nitrocellulose membranes, and probed with
. Immunoreactions of EgAg5 (purple), EgAgB1 subunit (blue), EgAgB1
icated. All signals were detected by ECL after 2 min exposure. Spots at
ity (box, left panel). Each corresponding band from CE1 and CE2 HF
oteins within box in A by PMF. (C) Immunoreactivity of each spot in
protein spots. The open bars indicate the relative volumes (left Y-axis)
solid bars indicate the relative volumes of the immunoblot.
Figure 3 Changes of immunoproteome profile according to CE progression. Blots containing CE2 HF were probed with individual CE1-CE5
sera as described in the Methods section. Markings are the same as in Figure 2A. Panels A-E show representative immunoblot images from
respective disease stages (CE1-CE5). Mr, molecular weights in kDa; pI, isoelectric point.
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dissimilar immune recognition patterns as compared
to those of CE1; reactions against EgAgB subunits,
especially against 8 kDa isoforms became evident with
growing frequency (75-100%), with the exception of
spot 61 (33.3%). Cathepsin B (spot 9) and EgAg5 (spots
23–26) also showed positive responses (75–91.7%)
(panel B). As the disease progressed to the transitional
CE3 stage, a variety of EgAgB isoforms (spots 44–48,
61, 63, 66, 67, 69, 72–75, and 77) exhibited prominent
antibody responses (75-100%). EgAg5 (spots 23–26)
also revealed positive reactions. In this stage, five to
seven spots located at approximately 24 kDa, which
were identified as various EgAgB isoforms (Figure 2B),
demonstrated positive reactions as well (panel C). As
the disease progressed to inactive CE4 and CE5 stages,
the immunoproteome profile regressed toward that
observed in CE1. Cathepsin B (spot 9) and 38 kDa EgAg5
subunits (spots 23–26) retained their responsiveness
(30.8-85.7%), while EgAgB proteoforms revealed signifi-
cantly decreased antibody capturing activity (0–63.6%)
(panels D and E).Assessment of cross-reactivity
We determined whether or not the proteins that showed
high immunoreactivity against CE sera cross-reacted with
heterologous infection sera and hepatocellular carcinoma
patient sera. When pooled serum of AE patients (n =10)
was probed with CE2 HF, cathepsin B (spots 7 and 9),
EgAg5 (spots 23–26), EgAgB2 (spot 75), and some
EgAgB1 isoforms (spots 44–48, 61–64, 66–69, 71–74,
and 77) exhibited serological cross-reactions. Further
analyses employing individual AE sera demonstrated
cross-reactivity of EgAg5 (70-80%) and EgAgB1 (20-50%)
with a complicated pattern (Figure 4A). Pooled serum
(each of n = 10) or individual sera of neurocysticercosis
and sparganosis also exhibited weak cross-reactions with
certain isoforms of EgAg5 (spots 23–26) and EgAgB
(spots 66, 73, and 75) (Figure 4B and C). Serological
cross-reactions between CE and AE may be inherent to
some extent due to the highly conserved sequence identity
between EgAgBs and EmAgBs (78.8-94.2%), except for the
antigen B3 series (36.5%) (data not shown), which did not
invoke a significant antibody response against CE patients.
Primary hepatocellular carcinoma patient sera and sera of
Figure 4 Cross-reactivity with other pathological conditions and normal controls. Blots containing CE2 HF were reacted with individual/
pooled (n = 10 per group) serum of AE (A), neurocysticercosis (B), sparganosis (C), primary hepatocellular carcinoma (D), and normal controls
(E). EgAgB1 shows cross-reactivity with AE patient sera (boxes in panel A). Markings are the same as in Figure 2A. AE, alveolar echinococcosis; NC,
neurocysticercosis; HCC, primary hepatocellular carcinoma. Mr, molecular weights in kDa; pI, isoelectric point.
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reactivity (Figure 4D and E). Table 2 summarizes the
evaluation of sensitivity and specificity of important
diagnostic spots by 2-DE/immunoblotting.
Discussion
In this study, we have undertaken a comprehensive
proteome analysis of CE1 and CE2 HF and identified 78
individual protein spots (40 Echinococcus and 38 host
proteins), in which EgAgB (28 species) and EgAg5 (5
molecules) were most abundantly recognized. Among the
EgAgB series, EgAgB1 represented the most profoundly
expressed proteoforms regardless of CE status, which wasconsistent with previous proteomic analysis of ovine CE
HF [21]. We subsequently determined the antigenic
properties of the respective proteoforms along with CE
progression and established a global CE immunoproteome
profile for the first time.
Our results demonstrated that immune recognition
patterns of CE patients were altered along with the
disease progression and they differed from one another.
In both the early CE1, and the chronic inactive CE4
and CE5 stages, EgAg5 played a major role in inducing
antibody responses. This result suggests that posttran-
slationally modified, externally exposed phosphorylcho-
line moieties of the EgAg5 (a major antigenic epitope),
Table 2 Responsiveness of major antigenic spots of E. granulosus HF
Spot no.
(Descriptiona)





















9 (Cathepsin B) 5 (45.5) 9 (75 ) 12 (100) 4 (30.8) 6 (85.7) 36 (61) 3 (30) 9 (90) 30 (100) 42 (84)
23 (38 kDa EgAg5) 4 (36.4) 11 (91.7) 12 (100) 7 (53.9) 9 (81.8) 43 (72.9) 2 (20) 6 (60) 30 (100) 38 (76)
24 (38 kDa EgAg5) 5 (45.5) 10 (83.3) 12 (100) 8 (61.5) 8 (72.7) 43 (72.9) 2 (20) 6 (60) 30 (100) 38 (76)
25 (38 kDa EgAg5) 6 (54.5) 10 (83.3) 12 (100) 8 (61.5) 8 (72.7) 44 (74.6) 2 (20) 6 (60) 30 (100) 38 (76)
26 (38 kDa EgAg5) 8 (72.7) 10 (83.3) 12 (100) 7 (53.8) 9 (81.8) 46 (80.0) 3 (30) 6 (60) 30 (100) 39 (78)
44 (EgAgB1/1) 0 (0) 10 (83.3) 10 (83.3) 7 (53.8) 0 (0) 27 (45.8) 8 (80) 10 (100) 30 (100) 48 (96)
45 (EgAgB1/1) 0 (0) 9 (75) 10 (83.3) 6 (46.2) 0 (0) 25 (42.4) 7 (70) 10 (100) 30 (100) 47 (94)
46 (EgAgB1/1) 0 (0) 10 (83.3) 11 (91.7) 5 (38.5) 0 (0) 26 (44.1) 8 (80) 10 (100) 30 (100) 48 (96)
47 (EgAgB1/1) 4 (36.4) 10 (83.3) 10 (83.3) 6 (46.2) 0 (0) 30 (50.8) 8 (80) 10 (100) 30 (100) 48 (96)
48 (EgAgB1/1) 3 (27.3) 9 (75) 10 (83.3) 5 (38.5) 0 (0) 27 (45.8) 7 (70) 10 (100) 30 (100) 47 (94)
61 (EgAgB1/1) 1 (9.1) 4 (33.3) 9 (75) 5 (38.5) 3 (27.3) 22 (37.3) 6 (60) 10 (100) 30 (100) 46 (92)
63 (EgAgB1/1) 4 (36.4) 9 (75) 12 (100) 7 (53.9) 6 (54.5) 38 (64.4) 7 (70) 10 (100) 30 (100) 47 (94)
66 (EgAgB1/1) 6 (54.5) 10 (83.3) 12 (100) 11 (84.6) 5 (45.5) 44 (74.6) 5 (50) 8 (80) 28 (93.3) 41 (82)
67 (EgAgB1/1) 5 (45.5) 9 (75) 12 (100) 5 (38.5) 2 (18.2) 33 (55.9) 7 (70) 10 (100) 30 (100) 47 (94)
69 (EgAgB1/1) 5 (45.5) 9 (75) 12 (100) 7 (53.8) 0 (0) 33 (55.9) 6 (60) 10 (100) 30 (100) 46 (92)
72 (EgAgB1 subunit) 6 (54.5) 10 (83.3) 12 (100) 10 (76.9) 7 (63.6) 45 (76.3) 7 (70) 10 (100) 30 (100) 47 (94)
73 (EgAgB1/1) 5 (45.6) 11 (91.7) 12 (100) 4 (30.8) 0 (0) 32 (54.2) 5 (50) 8 (80) 29 (96.7) 42 (84)
74 (EgAgB1/1) 4 (36.4) 10 (83.3) 12 (100) 5 (38.5) 4 (36.4) 32 (54.2) 7 (70) 10 (100) 30 (100) 47 (94)
75 (EgAgB2) 4 (36.4) 10 (83.3) 12 (100) 5 (38.5) 4 (36.4) 35 (59.3) 5 (50) 7 (70) 30 (100) 42 (84)
77 (EgAgB1/1) 4 (36.4) 12 (100) 12 (100) 5 (38.5) 6 (54.5) 39 (66.1) 6 (60) 10 (100) 30 (100) 46 (92)
aProtein names were adapted from the GenBank database.
bOthers included sparganosis, primary hepatocellular carcinoma, and normal controls (each of n = 10).
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although its specificity is fairly low. EgAg5 is a high-
molecular-weight glycoprotein complex (>500 kDa)
consisting of 57 and 67 kDa under reducing conditions,
and is dissociated into 22 and 38 kDa subunits [22]. The
protein has been widely used for CE immunodiagnosis,
while other studies have demonstrated that EgAg5
cross-reacted with the patient sera of other helminthic
infections [12,23]. Indeed, several EgAg5 molecules
showed cross-reactions with AE and neurocysticercosis
sera (Figure 4 and Table 2). In the early stage of CE, the
immunoreactivity of EgAgB isoforms was reasonably
weak. Previous studies involving animal CE immunodi-
agnosis revealed that EgAgB demonstrated quite low
sensitivity [24,25]. This result strongly suggested that
these animals, even infected, might be in an early stage of
CE since the cattle slaughtered in abattoirs are mostly
young. Sera from these animals might not respond to
EgAgB as shown in this study. These collective results
indicated that EgAgB proteoforms may not be applicable
for serodiagnosis of early and chronic stages of CE.
As cyst(s) develops and progresses into the active
stage, a substantially expanded germinal layer synthe-
sizes and secretes copious quantities of several tens ofEgAgB, and induces antibody responses. In the transi-
tional CE3 period, previously secreted diverse EgAgB
molecules continuously stimulate the immune system. A
partially degenerative germinal layer might maintain its
capacity to produce and secret EgAgBs, which results in
the strong antibody responses, as is seen in this study.
Among several EgAgB proteoforms, EgAgB1 constituted
the majority with the strongest antigenicity. When meta-
cestode(s) regressed to chronic inactive stages, EgAgB-
enriched HF might be rapidly drained and become
absorbed through degenerative membranes. Subse-
quently, the synthesis of EgAgB might also be attenu-
ated and the antibody responses culminating to EgAgB
would become negligible. A similar phenomenon has been
observed in neurocysticercosis, which is caused by a
phylogentically-close neighbor, the Taenia solium meta-
cestode. Expression of a 150-kDa hydrophobic-ligand-
binding-protein (HLBP) complex, which invokes specific
and strong antibody reactions during the active stage, is
drastically down-regulated as the parasite undergoes de-
generation by calcification [26,27]. This common pattern
of expressional regulation of HLBPs may have significant
pathophysiological implications in the long-term survival
of larval taeniid, such as E. granulosus and T. solium
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are critical in recruiting essential host lipids, regulating
local immune responses, and modulating protein turn-
over [17,26,27]. This result also raised an intriguing
suggestion that blocking the synthesis or inactivating
these molecules might be an attractive target to control
CE and neurocysticercosis. Molecular mechanisms
underlining expressional regulation of several EgAgB pro-
teoforms should form the basis of future studies.
The EgAgB2 appeared to be a reliable antigenic pro-
tein for CE serodiagnosis, when the HFs of bovine and
human origin were employed as antigens [28]. However,
such a potent immunoreactivity of EgAgB2 proteoforms
was not observed with ovine CE2 HF in this study. It
would be interesting to analyze whether the expressions
of different EgAgBs are differentially regulated in different
hosts. We could not detect individual EgAgB3-related
molecules through 2-DE analysis. These molecules were
only identifiable by LC-ESI-MS/MS. Since EgAgB3 is
primarily synthesized in the protoscolex [29], our result
suggests that, although transcription levels of EgAgB3 are
relatively high in the protoscolex [14], secretion of
EgAgB3 at protein levels would be minimal, and corre-
lated with the finding that its antigenicity was reasonably
weak and was detected only in the active and transitional
periods, during which active immune systems are operat-
ing (Figure 3). In addition, we were unable to detect
EgAgB5 molecules, which harbored similar primary
sequences to EgAgB3 molecules. This isoform was indeed
shown to be mainly expressed in the immature adult, but
not the metacestode, stage [14,21].
CE cyst thrives for over 20 years in immunologically
competent hosts. The parasite continuously interacts with
the host to defend the cytopathic environment. In addition
to diverse EgAgB, HF contains many secretory proteins,
which may contribute to parasite survival through the
regulation of bioactive molecules [29,30]. Some metabolic
enzymes, especially those involved in carbohydrate metab-
olism, are known to perform several moonlighting activ-
ities [31-33]. We identified multifaceted E. granulosus
protein enzymes, such as phosphoenolpyruvate carboxyki-
nase (maintenance of cytosolic and mitochondrial redox
balance, and induction of T-cell immunity), citrate syn-
thase (chaperon activity, growth, and virulence), fructose
1,6 bisphosphate aldolase (cellular adhesion and antioxi-
dant activity), and triosephosphate isomerase (anti-oxida-
tive processes and glutathione redox cycle) [33-36]. In
this study, we were able to detect host-derived serum
components, antioxidant/detoxification/xenobiotic pro-
teins, enzymes involved in carbohydrate and amino acid
metabolism, and fatty-acid-binding proteins, which might
be absorbed through transporter-mediated-uptake or endo-
cytosis [26,37]. These proteins might exert their moonlight-
ing effects within the HF. Dynamic molecular biochemicaland cellular events might be actively occurring within the
HF, and Echinococcus might absorb and exploit these mole-
cules to maintain its homeostatic function [36]. Further
research is warranted to explicate the biological roles of in-
dividual proteins together with the molecular network and
cross-talk functions within the HF.
Conclusions
Early detection of CE may have a great impact on reduc-
tion of disability-adjusted life years, because the highest
morbidity is observed in young patients under 20 years
old [1,5]. Our results convincingly demonstrate that the
detection of a single defined molecule may not properly
diagnose CE since specific immunopotent antigens are
altered according to CE progression. Serological cross-
reactions between CE and AE may be inherent to some
extent. Surveillance of immunoproteome characteristics
combined with imaging scans may be essential to differ-
entiate CE from AE and to clarify CE status. Our data
also highlighted the possible biological functions of HF
proteins, which might be intimately involved in the
homeostatic maintenance and pathophysiological adap-
tation of the parasite during long-standing infections.
Additional files
Additional file 1: Demographic and clinical features of CE patients
enrolled in this study.
Additional file 2: Protein identification of sheep CE1 and CE2 HF
following MALDI-TOF-MS analysis.
Abbreviations
AE: Alveolar echinococcosis; CBB: Coomassie brilliant blue G-250; CE: Cystic
echinococcosis; EgAgB: Echinococcus granulosus antigen B; EgAg5: Echinococcus
granulosus antigen 5; HRP: Horse-radish peroxidase; HF: Hydatid fluid;
HLBP: Hydrophobic-ligand-binding-protein; IPG: Immobilized pH gradient;
MALDI-TOF-MS: Matrix-assisted laser desorption/ioninzation time-of-flight mass
spectrometry; nano-LC-ESI-MS/MS: Nano-liquid chromatography-electrospray
ionization/multi-stage MS; ECL: SuperSignal chemiluminescence; PMF: Peptide
mass fingerprint; 2-DE: Two-dimensional electrophoresis; US: Ultrasonography.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Experimental conception and design: YK; sample collection: XH, XM, HC, HJY,
CSA, JTK, HW; field survey: XH, XM, HC, HJY, YK, HW; 2-DE and immunoblot:
CSA, YAB, JTK, IK; proteome analyses: CSA, IK, YAB, YK; paper writing: YK, CSA.
All authors read and approved the final version of the manuscript.
Acknowledgements
We thank all local health workers of Qinghai Province Institute for Endemic
Diseases Prevention and Control, China, who helped us during the survey of
the patients. This work was supported by a grant from Samsung Biomedical
Research Institute (SMX1132101).
Author details
1Department of Molecular Parasitology, Sungkyunkwan University School of
Medicine and Center for Molecular Medicine, Samsung Biomedical Research
Institute, Suwon 440-746, Korea. 2Qinghai Province Institute for Endemic
Diseases Prevention and Control, Xining, Qinghai, China. 3Department of
Microbiology, Graduate School of Medicine, Gachon University, Incheon,
Ahn et al. Parasites & Vectors  (2015) 8:10 Page 10 of 10Korea. 4Department of Parasitology, Ewha Womans University, School of
Medicine, Seoul, Korea. 5Department of Molecular Biology and Biochemistry,
School of Medicine, Kyung Hee University, Seoul, Korea.
Received: 30 September 2014 Accepted: 17 December 2014References
1. Eckert J, Deplazes P: Biological, epidemiological, and clinical aspects of
echinococcosis, a zoonosis of increasing concern. Clin Microbiol Rev 2009,
27:107–135.
2. Zhang W, Zhang Z, Wu W, Shi B, Li J, Zhou X, Wen H, McManus DP:
Epidemiology and control of echinococcosis in central Asia, with
particular reference to the People’s Republic of China. Acta Trop 2014.
http://dx.doi.org/10.1016/j.actatropica.2014.03.014.
3. Yang YR, Clements AC, Gray DJ, Atkinson JA, Williams GM, Barnes TS,
McManus DP: Impact of anthropogenic and natural environmental
changes on Echinococcus transmission in Ningxia Hui Autonomous
Region, the People’s Republic of China. Parasit Vectors 2012, 5:146.
4. Craig PS, McManus DP, Lightowlers MW, Chabalgoity JA, Garcia HH, Gavidia
CM, Gilman RH, Gonzalez AE, Lorca M, Naquira C, Nieto A, Schantz PM:
Prevention and control of cystic echinococcosis. Lancet Infect Dis 2007,
7:385–394.
5. Brunetti E, Kern P, Vuitton DA: Writing panel for the WHO-IWGE. expert
consensus for the diagnosis and treatment of cystic and alveolar
echinococcosis in humans. Acta Trop 2010, 114:1–16.
6. Caremani M, Maestrini R, Occhini U, Sassoli S, Accorsi A, Giorgio A, Filice C:
Echographic epidemiology of cystic hydatid disease in Italy. Eur J
Epidemiol 1993, 9:401–404.
7. Perdomo R, Alvarez C, Monti J, Ferreira C, Chiesa A, Carbó A, Alvez R, Grauert R,
Stern D, Carmona C, Yarzabal L: Principles of the surgical approach in human
liver cystic echinococcosis. Acta Trop 1997, 64:109–122.
8. Eckert J, Gemmell MA, Meslin FX, Pawlowski ZS: WHO/OIE Manual on
Echinococcosis in Humans and Animals: a Public Health Problem of Global
Concern. Paris: WHO/OIE; 2001.
9. Taheri MS, Pourghorban R, Faghihi Langroudi T, Shabestari AA,
Haghighatkhah H, Bagheri SM: Not-to-tap cystic lesions: spectrum of
hydatid disease. Emerg Radiol 2013, 20:553–561.
10. Siracusano A, Margutti P, Delunardo F, Profumo E, Riganò R, Buttari B,
Teggi A, Ortona E: Molecular cross-talk in host-parasite relationships: the
intriguing immunomodulatory role of Echinococcus antigen B in cystic
echinococcosis. Int J Parasitol 2008, 38:1371–1376.
11. Ortona E, Riganò R, Margutti P, Notargiacomo S, Ioppolo S, Vaccari S, Barca S,
Buttari B, Profumo E, Teggi A, Siracusano A: Native and recombinant antigens
in the immunodiagnosis of human cystic echinococcosis. Parasite Immunol
2000, 22:553–559.
12. Lorenzo C, Last JA, González-Sapienza GG: The immunogenicity of
Echinococcus granulosus antigen 5 is determined by its post-translational
modifications. Parasitology 2005, 131:669–677.
13. Haag KL, Alves-Junior L, Zaha A, Ayala FJ: Contingent, non-neutral evolution
in a multicellular parasite: natural selection and gene conversion in the
Echinococcus granulosus antigen B gene family. Gene 2004, 333:157–167.
14. Zhang W, Li J, Jones MK, Zhang Z, Zhao L, Blair D, McManus DP: The
Echinococcus granulosus antigen B gene family comprises at least 10
unique genes in five subclasses which are differentially expressed.
PLoS Negl Trop Dis 2010, 4:e784.
15. Shepherd JC, Aitken A, McManus DP: A protein secreted in vivo by
Echinococcus granulosus inhibits elastase activity and neutrophil
chemotaxis. Mol Biochem Parasitol 1991, 44:81–90.
16. Daeki AO, Craig PS, Shambesh MK: IgG-subclass antibody responses and
the natural history of hepatic cystic echinococcosis in asymptomatic
patients. Ann Trop Med Parasitol 2000, 94:319–328.
17. Obal G, Ramos AL, Silva V, Lima A, Batthyany C, Bessio MI, Ferreira F, Salinas
G, Ferreira AM: Characterisation of the native lipid moiety of Echinococcus
granulosus antigen B. PLoS Negl Trop Dis 2012, 6:e1642.
18. Junghanss T, da Silva AM, Horton J, Chiodini PL, Brunetti E: Clinical
management of cystic echinococcosis: state of the art, problems, and
perspectives. Am J Trop Med Hyg 2008, 79:301–311.
19. Mariconti M, Bazzocchi C, Tamarozzi F, Meroni V, Genco F, Maserati R,
Brunetti E: Immunoblotting with human native antigen shows stage-related sensitivity in the serodiagnosis of hepatic cystic echinococcosis.
Am J Trop Med Hyg 2014, 90:75–79.
20. Bae YA, Jeong YT, Chung JY, Kim SH, Mahanta J, Feng Z, Chong CK, Kim TS,
Kong Y: A recombinant chimeric antigen toward a standardized
serodiagnosis of Taenia solium neurocysticercosis. Proteomics Clin Appl
2008, 2:1596–1610.
21. Monteiro KM, Cardoso MB, Follmer C, da Silveira NP, Vargas DM, Kitajima EW,
Zaha A, Ferreira HB: Echinococcus granulosus antigen B structure: subunit
composition and oligomeric states. PLoS Negl Trop Dis 2012, 6:e1551.
22. Lightowlers MW, Liu DY, Haralambous A, Rickard MD: Subunit composition
and specificity of the major cyst fluid antigens of Echinococcus
granulosus. Mol Biochem Parasitol 1989, 37:171–182.
23. Khabiri AR, Bagheri F, Assmar M, Siavashi MR: Analysis of specific IgE and
IgG subclass antibodies for diagnosis of Echinococcus granulosus. Parasite
Immunol 2006, 28:357–362.
24. Ibrahem MM, Rafiei A, Dar FK, Azwai SM, Carter SD, Craig PS: Serodiagnosis
of cystic echinococcosis in naturally infected camels. Parasitology 2002,
125:245–251.
25. McManus DP: Immunodiagnosis of sheep infections with Echinococcus
granulosus: in 35 years where have we come? Parasite Immunol 2004,
36:125–130.
26. Lee EG, Kim SH, Bae YA, Chung JY, Suh M, Na BK, Kim TS, Kang I, Ma L, Kong Y:
A hydrophobic ligand binding protein of the Taenia solium metacestode
mediates uptake of the host lipid: implication for the maintenance of
parasitic cellular homeostasis. Proteomics 2007, 7:4016–4030.
27. Kim SH, Bae YA, Yang Y, Hong ST, Kong Y: Paralogous proteins comprising
the 150 kDa hydrophobic-ligand-binding-protein complex of the Taenia
solium metacestode have evolved non-overlapped binding affinities
toward fatty acid analogs. Int J Parasitol 2011, 41:1207–1215.
28. Virginio VG, Hernández A, Rott MB, Monteiro KM, Zandonai AF, Nieto A,
Zaha A, Ferreira HB: A set of recombinant antigens from Echinococcus
granulosus with potential for use in the immunodiagnosis of human
cystic hydatid disease. Clin Exp Immunol 2003, 132:309–315.
29. Virginio VG, Monteiro KM, Drumond F, de Carvalho MO, Vargas DM, Zaha A,
Ferreira HB: Excretory/secretory products from in vitro-cultured
Echinococcus granulosus protoscoleces. Mol Biochem Parasitol 2012,
183:15–22.
30. Cui SJ, Xu LL, Zhang T, Xu M, Yao J, Fang CY, Feng Z, Yang PY, Hu W, Liu F:
Proteomic characterization of larval and adult developmental stages in
Echinococcus granulosus reveals novel insight into host-parasite
interactions. J Proteomics 2013, 84:158–175.
31. Gancedo C, Flores C: Moonlighting proteins in yeasts. Microbiol Mol Biol
Rev 2008, 72:197–210.
32. Pomel S, Luk FC, Beckers CJ: Host cell egress and invasion induce marked
relocations of glycolytic enzymes in Toxoplasma gondii tachyzoites. PLoS
Pathog 2008, 4:e1000188.
33. Lorenzatto KR, Monteiro KM, Paredes R, Paludo GP, da Fonsêca MM, Galanti N,
Zaha A, Ferreira HB: Fructose-bisphosphate aldolase and enolase from
Echinococcus granulosus: genes, expression patterns and protein
interactions of two potential moonlighting proteins. Gene 2012, 506:76–84.
34. Buchner J, Grallert H, Jakob U: Analysis of chaperone function using
citrate synthase as nonnative substrate protein. Methods Enzymol 1998,
290:323–338.
35. Asahi H, Osman A, Cook RM, LoVerde PT, Stadecker MJ: Schistosoma
mansoni phosphoenolpyruvate carboxykinase, a novel egg antigen:
immunological properties of the recombinant protein and identification
of a T-cell epitope. Infect Immun 2000, 68:3385–3393.
36. Monteiro KM, de Carvalho MO, Zaha A, Ferreira HB: Proteomic analysis of
the Echinococcus granulosus metacestode during infection of its
intermediate host. Proteomics 2010, 10:1985–1999.
37. Ambrosio J, Landa A, Merchant MT, Laclette JP: Protein uptake by cysticerci
of Taenia crassiceps. Arch Med Res 1994, 25:325–330.
